Intratracheal injection of dendritic cells loaded with cytotoxic T cell epitope of intracellular pathogen efficiently induces epitope-specific T cells and confers protective immunity
气管内注射负载细胞内病原体细胞毒性T细胞表位的树突状细胞,可有效诱导表位特异性T细胞并赋予保护性免疫
基本信息
- 批准号:17590784
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2005
- 资助国家:日本
- 起止时间:2005 至 2006
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The present study was conducted to develop an effective mucosal cell-vaccine against infection of intracellular pathogen. Bone-marrow derived mouse dendritic cells were treated with LPS for 16 hrs, and pulsed with dominant cytotoxic T cell (CTL) epitope, LLO91-99, derived from lysteriolysin O of Listeria monocytogenesis (LM). Then, LLO-loaded dendritic cells were intratracheally instilled. Tracheal injection of LLO-loaded dendritic cells induced LLO-specific CTL determined by tetramers, and LLO-specific IFN-gamma production from regional lymph nodes. In a mouse model of pulmonary LM infection, vaccinated mouse showed a significant decrease in bacterial doses compared with naive mouse. Moreover, this dendritic cell-vaccine protected them from lethal LM infection. Taken together, these results suggest that intratracheal administration of dendritic cells loaded with a dominant CTL epitope against intracellular pathogen is an effective mucosal vaccine, which induces protective immunity the mucosal sites as well as systemic immunity.
本研究旨在研制一种有效的抗细胞内病原体感染的粘膜细胞疫苗。用LPS处理骨髓来源的小鼠树突细胞16小时,并用来源于单核细胞生成李斯特菌(LM)的溶血素O的显性细胞毒性T细胞(CTL)表位LLO 91 -99脉冲。然后,将负载LLO的树突状细胞进行气管内滴注。气管注射负载LLO的树突状细胞诱导由四聚体确定的LLO特异性CTL,以及局部淋巴结产生的LLO特异性IFN-γ。在肺部LM感染的小鼠模型中,与未接种小鼠相比,接种小鼠显示细菌剂量显著降低。此外,这种树突状细胞疫苗可以保护他们免受致命的LM感染。总之,这些结果表明,肠道内施用负载有针对细胞内病原体的优势CTL表位的树突状细胞是有效的粘膜疫苗,其诱导粘膜部位的保护性免疫以及全身免疫。
项目成果
期刊论文数量(21)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Quantitative analysis of fibroblastic foci in usual interstitial pneumonia
- DOI:10.1378/chest.130.1.22
- 发表时间:2006-07-01
- 期刊:
- 影响因子:9.6
- 作者:Enomoto, Noriyuki;Suda, Takafumi;Chida, Kingo
- 通讯作者:Chida, Kingo
Identification of HLAA*0201-Restricted T-Cell Epitope on MPT51 Protein, a Major Secreted Protein Derived from Mycobacterium tuberculosis using MPT5 1 Overlappin, Peptides Screening.
使用 MPT5 1 Overlappin、肽筛选鉴定 MPT51 蛋白(结核分枝杆菌衍生的主要分泌蛋白)上的 HLAA*0201 限制性 T 细胞表位。
- DOI:
- 发表时间:2008
- 期刊:
- 影响因子:0
- 作者:Aoshi T;Nagata T;Suzuki M;et. al.
- 通讯作者:et. al.
Correlation between peripheral blood T-cell profiles and airway inflammation in atopic asthma.
外周血 T 细胞谱与特应性哮喘气道炎症之间的相关性。
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Shirai T;Inui N;Suda T;et. al.
- 通讯作者:et. al.
alpha-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation.
- DOI:
- 发表时间:2005
- 期刊:
- 影响因子:6.4
- 作者:H. Matsuda;T. Suda;J. Sato;T. Nagata;Y. Koide;K. Chida;Hirotoshi Nakamura
- 通讯作者:H. Matsuda;T. Suda;J. Sato;T. Nagata;Y. Koide;K. Chida;Hirotoshi Nakamura
Lung dendritic cells have a potent capability to induce production 0f immunoglobulin A.
肺树突状细胞具有诱导产生 0f 免疫球蛋白 A 的强大能力。
- DOI:
- 发表时间:2008
- 期刊:
- 影响因子:0
- 作者:Naito T;Suda T;Suzuki K;et. al.
- 通讯作者:et. al.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUDA Takafumi其他文献
SUDA Takafumi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUDA Takafumi', 18)}}的其他基金
Novel dendritic cell vaccine for tuberculosis with inhibition of indoleamine 2, 3-dioxygenase.
抑制吲哚胺 2, 3-双加氧酶的新型结核病树突状细胞疫苗。
- 批准号:
21590985 - 财政年份:2009
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of dendritic cell vaccine modified with a ligand of NKT cells against tuberculosis
开发用 NKT 细胞配体修饰的抗结核树突状细胞疫苗
- 批准号:
19590888 - 财政年份:2007
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of anti-tuberculosis vaccine using cytokine gene-transduced dendritic cells
使用细胞因子基因转导的树突状细胞开发抗结核疫苗
- 批准号:
15590803 - 财政年份:2003
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of DC-vaccine against tuberclulosis
抗结核 DC 疫苗的研制
- 批准号:
13670595 - 财政年份:2001
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Involvement of dendritic cells in pulmonary granuloma formation elicited by BCG in rats
树突状细胞参与卡介苗诱导的大鼠肺肉芽肿形成
- 批准号:
11670572 - 财政年份:1999
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Understanding of causal links between gut microbiota and mucosal vaccine efficacy
了解肠道微生物群与粘膜疫苗功效之间的因果关系
- 批准号:
23K13877 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection
一种针对铜绿假单胞菌感染的新型粘膜疫苗
- 批准号:
10446501 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Optimization for Zika virus oral mucosal vaccine using recombinant saccharomyces and lactobacilli
使用重组酵母菌和乳酸杆菌优化寨卡病毒口腔粘膜疫苗
- 批准号:
22K10495 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel Nanoparticle Respiratory Tract Mucosal Vaccine
新型纳米颗粒呼吸道粘膜疫苗
- 批准号:
10442173 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Novel Nanoparticle Respiratory Tract Mucosal Vaccine
新型纳米颗粒呼吸道粘膜疫苗
- 批准号:
10599198 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
NOVEL MUCOSAL VACCINE APPROACHES FOR PNEUMONIA KLEBSIELLA
治疗克雷伯氏肺炎的新型粘膜疫苗方法
- 批准号:
10863795 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection
一种针对铜绿假单胞菌感染的新型粘膜疫苗
- 批准号:
10550157 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
A Novel Th17-inducing Mucosal Vaccine for Tuberculosis
一种新型 Th17 诱导型结核粘膜疫苗
- 批准号:
10757098 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别:
Development of a mucosal vaccine to prevent Clostridium difficile infection using papilloma pseudovirus as a vector.
使用乳头状瘤假病毒作为载体开发粘膜疫苗以预防艰难梭菌感染。
- 批准号:
10213890 - 财政年份:2020
- 资助金额:
$ 2.24万 - 项目类别: